Prima BioMed Total Assets 2010-2021 | IMMP

Prima BioMed total assets from 2010 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Prima BioMed Annual Total Assets
(Millions of US $)
2021 $61
2020 $31
2019 $29
2018 $36
2017 $26
2016 $31
2015 $26
2014 $21
2013 $34
2012 $43
2011 $57
2010 $17
2009 $2
Prima BioMed Quarterly Total Assets
(Millions of US $)
2017-03-31 $27
2016-12-31 $29
2016-06-30 $31
2015-12-31 $37
2015-06-30 $26
2014-12-31 $34
2014-06-30 $21
2013-12-31 $30
2013-06-30 $34
2012-12-31 $34
2012-06-30 $43
2011-06-30 $57
2010-06-30 $17
2009-06-30 $2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.209B $0.003B
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00